Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Modern Chinese Medicine Group Co. Ltd. ( (HK:1643) ) just unveiled an update.
Modern Chinese Medicine Group Co., Ltd. announced that its board of directors will convene a meeting on 30 March 2026 to review and approve the audited annual results for the year ended 31 December 2025. At the same meeting, the board will also consider whether to recommend a final dividend, a decision that could signal the company’s earnings strength and capital allocation priorities to shareholders.
The announcement underscores upcoming disclosure of full-year financial performance, which may influence investor sentiment toward the stock depending on revenue, profit trends, and any proposed shareholder returns. With a balanced board comprising executive and independent non-executive directors, the company’s decisions on results approval and potential dividend distributions are positioned within an established governance framework aimed at aligning management and shareholder interests.
The most recent analyst rating on (HK:1643) stock is a Hold with a HK$0.91 price target. To see the full list of analyst forecasts on Modern Chinese Medicine Group Co. Ltd. stock, see the HK:1643 Stock Forecast page.
More about Modern Chinese Medicine Group Co. Ltd.
Modern Chinese Medicine Group Co., Ltd. is a Hong Kong-listed company incorporated in the Cayman Islands and engaged in the Chinese medicine sector. The company is governed by a board that includes three executive directors and three independent non-executive directors, reflecting a standard corporate governance structure for a mid-sized listed enterprise.
Average Trading Volume: 2,131,929
Technical Sentiment Signal: Buy
Current Market Cap: HK$950.4M
See more data about 1643 stock on TipRanks’ Stock Analysis page.